Grace Therapeutics, Stock Current Ratio
| GRCE Stock | 3.58 0.32 8.21% |
Grace Therapeutics, fundamentals help investors to digest information that contributes to Grace Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Grace Stock. The fundamental analysis module provides a way to measure Grace Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Grace Therapeutics, stock.
Grace | Current Ratio |
Grace Therapeutics, Company Current Ratio Analysis
Grace Therapeutics,'s Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Grace Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Grace Therapeutics, is extremely important. It helps to project a fair market value of Grace Stock properly, considering its historical fundamentals such as Current Ratio. Since Grace Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Grace Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Grace Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Grace Therapeutics, has a Current Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current ratio for all United States stocks is 100.0% higher than that of the company.
Grace Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Grace Therapeutics,'s direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Grace Therapeutics, could also be used in its relative valuation, which is a method of valuing Grace Therapeutics, by comparing valuation metrics of similar companies.Grace Therapeutics, is currently under evaluation in current ratio category among its peers.
Grace Fundamentals
| Net Income | (12.85 M) | ||||
| Total Debt | 11.56 M | ||||
| Cash Flow From Operations | (12.33 M) | ||||
| Total Asset | 73.3 M | ||||
| Retained Earnings | (211.12 M) | ||||
| Working Capital | 22.33 M | ||||
| Net Asset | 73.3 M |
About Grace Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Grace Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Grace Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Grace Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Grace Therapeutics, is a strong investment it is important to analyze Grace Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Grace Therapeutics,'s future performance. For an informed investment choice regarding Grace Stock, refer to the following important reports:Check out Grace Therapeutics, Piotroski F Score and Grace Therapeutics, Altman Z Score analysis. For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Grace Therapeutics,. If investors know Grace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Grace Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Grace Therapeutics, is measured differently than its book value, which is the value of Grace that is recorded on the company's balance sheet. Investors also form their own opinion of Grace Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Grace Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Grace Therapeutics,'s market value can be influenced by many factors that don't directly affect Grace Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Grace Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Grace Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.